Pyxis Oncology (PYXS) Cost of Revenue (2024 - 2025)

Pyxis Oncology (PYXS) posted quarterly Cost of Revenue of $2.4 million for Q4 2025, up 402.74% quarter-over-quarter from $475000.0 in Q1 2024.

Pyxis Oncology (PYXS) Cost of Revenue (2024 - 2025) Analysis & Trends

Pyxis Oncology (PYXS) has reported Cost of Revenue for 2 consecutive years, with $2.4 million the latest figure, recorded in Q4 2025.

In Q4 2025, Cost of Revenue changed N/A year-over-year to $2.4 million; the TTM figure through Dec 2025 stood at $2.4 million (up 402.74% YoY), while the FY2025 annual figure was $2.4 million, up 402.74% from the prior year.
Cost of Revenue advanced to $2.4 million in Q4 2025 per PYXS's latest filing, from $475000.0 in the prior quarter.
Across five years, Cost of Revenue topped out at $2.4 million in Q4 2025 and bottomed at $475000.0 in Q1 2024.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Cost of Rev (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn	489.20 Mn
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn	360.70 Mn
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn	145.00 Mn
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn	93.00 Mn
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn	174.53 Mn
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn	298.26 Mn
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn	387.98 Mn
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn	67.21 Mn
9	Royalty Pharma	27.27 Bn	26.43 Bn	-	-
10	Pyxis Oncology	198.37 Mn	165.38 Mn	-	-

Download Data